Because CJC-1295 acts upstream of growth hormone, its safety profile is tied to two overlapping issues: Peptide-specific effects , such as injection-site reactions or transient flushing GH/IGF-1-axis effects , such as fluid retention, joint discomfort, changes in glucose handling, or other effects associated with elevated growth hormone signaling The safety discussion is also complicated by naming
However, by days 3 and 7, the BIV was significantly increased in group 3 than in other groups, significantly increased in groups 4 and 5 than in groups 1 and 2 and significantly increased in group 4 than in group 5, but it showed no difference between groups 1 and 2 (Fig
85 LeeB
10.1007/s12035-018-1299-y 192 ZhangT.SuJ.GuoB.WangK.LiX.LiangG
They are indicated for type 2 diabetes management, weight reduction in obesity, and cardiovascular risk reduction, with ongoing investigation into metabolic dysfunction-associated steatohepatitis, chronic kidney disease, and heart failure with preserved ejection fraction
